Valuation: Tonix Pharmaceuticals

Market Cap 184M 162M 150M 138M 260M 17.73B 263M 1.79B 699M 8.69B 692M 677M 30.07B P/E 2026 *
-1.15x
P/E 2027 * -1.83x
Enterprise Value 184M 162M 150M 138M 260M 17.73B 263M 1.79B 699M 8.69B 692M 677M 30.07B EV / Sales 2026 *
5.39x
EV / Sales 2027 * 2.33x
Free-Float
99.86%
Yield 2026 *
-
Yield 2027 * -
07-15 Tonix Pharmaceuticals Advances Tnx-801 Live Attenuated Minimally Replicative Investigational Vaccine Candidate Based on Horsepox Virus to Protect Against Mpox Disease CI
07-13 Tonix Pharmaceuticals Holding Corp. Announces Major Managed Medicare Agreement for Tonmya and Expands Pharmacy Coverage CI
07-13 Tonix Pharmaceuticals Reaches Medicare Coverage Deal for Fibromyalgia Treatment MT
06-29 Tonix Pharmaceuticals Advances TNX-102 SL Into Phase 2 MDD Study MT
06-29 Tonix Pharmaceuticals Holding Corp Announces First Patient Enrolled in Phase 2 Horizon Study of TNX-102 SL For Major Depressive Disorder CI
06-25 Raymond James Initiates Coverage on Tonix Pharmaceuticals With Strong Buy Rating, $26 PT MT
06-08 Tonix Pharmaceuticals Enters Second Commercial Payer Deal, Expands Drug Coverage MT
06-08 Tonix Pharmaceuticals Holding Corp. Enters Agreement With Group Purchasing Organization For Commercial Coverage Of TONMYA CI
05-28 Tonix Pharmaceuticals Holding Corp. Presents Data from Real-World Claims Analysis of Opioid Use in U.S. Adults with Fibromyalgia at 2026 ASCP Annual Meeting CI
05-27 Tonix Pharmaceuticals Holding Corp. Announces Publication Of Phase 1 Clinical Data Of TNX-1500 Fc-Modified Anti-CD40L Monoclonal Antibody CI
05-26 Tonix Pharmaceuticals Presents Real-World Claims Analysis And Launches TONMYA For Fibromyalgia Treatment CI
05-11 Tranche Update on Tonix Pharmaceuticals Holding Corp.'s Equity Buyback Plan announced on September 6, 2024. CI
05-11 Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
Manager TitleAgeSince
Chief Executive Officer 68 2007-11-15
Director of Finance/CFO 52 2016-01-31
Chief Tech/Sci/R&D Officer 57 2025-02-03
Director TitleAgeSince
Director/Board Member 78 2018-02-12
Director/Board Member 66 2020-06-08
Director/Board Member 81 2018-09-04
Change 5-day change 1-year change 3-year change Capi.($)
-2.36%+2.32% - - 175M
+2.49%-0.55%+52.31%+153.42% 1,023B
+0.72%-2.78%+53.09%+48.84% 599B
+1.07%+3.27%+35.32%+80.11% 448B
+0.63%+0.94%+29.13%+21.91% 326B
+1.98%+0.77%+36.03%+38.03% 278B
+0.90%-0.94%+21.35%+16.79% 258B
-1.20%-0.11%-21.84%-41.31% 222B
+0.57%+1.61%+24.25%+57.03% 197B
-2.20%-0.85%+20.38%+62.97% 165B
Average -0.39%-0.38%+27.78%+48.64% 390.56B
Weighted average by Cap. -0.33%-1.18%+36.82%+72.99%

Financials

2026 *2027 *
Net sales 34.18M 29.99M 27.79M 25.56M 48.23M 3.29B 48.85M 332M 130M 1.61B 128M 126M 5.58B 78.93M 69.24M 64.17M 59.02M 111M 7.6B 113M 766M 300M 3.72B 296M 290M 12.88B
Net income -170M -149M -138M -127M -240M -16.36B -243M -1.65B -645M -8.02B -638M -624M -27.74B -152M -133M -123M -114M -214M -14.61B -217M -1.47B -576M -7.16B -570M -558M -24.78B
Net Debt - -
Logo Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
11.56USD
Average target price
42.20USD
Spread / Average Target
+265.05%

Quarterly revenue - Rate of surprise